MSP-4020

MSP-4020 is a patent-pending **small molecule psychedelic** drug candidate from Mindset Pharma being developed for neuropsychiatric and neurological disorders with unmet need. It is described as a next-generation, **5-MeO-DMT and DMT-inspired** compound within Mindset's Family 4 series, designed for in-clinic psychedelic treatment settings. In preclinical studies, MSP-4020 showed strong efficacy in the mouse head-twitch assay and an improved safety profile versus 5-MeO-DMT and related parent compounds, including no observed signs of 5-HT syndrome at tested doses up to 30 mg/kg. The precise receptor pharmacology and clinical indication have not been publicly disclosed, but the program was reported to be in preclinical development.